Product news
Indevus Pharmaceuticals has received a non-approvable letter from FDA for Valstar related to its chemistry, manufacturing and controls NDA supplement ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.